NCT01687244View on ClinicalTrials.gov

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

January 31, 2016

Conditions

Superficial Bladder Cancer

Interventions

DRUG

INSTILADRIN

The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.